Obesity is a medical disorder in which the body accumulates too much fat. Excessive food intake, hereditary vulnerability, and a lack of physical activity are all frequent causes of the Obesity Management Drugs Market. Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, and Liraglutide are some of the drugs used to treat obesity.
Over the forecast period, the worldwide Obesity Management Drugs Market is expected to rise due to the high prevalence of obesity. According to MedAlertHelp.org, nearly 1.9 billion adults globally are considered overweight.
Furthermore, obesity R&D is expected to contribute to the global obesity management drugs market's growth. According to a short study to be presented at e-ECE 2020, the 22nd European Congress of Endocrinology, the probiotic strain Bifidobacterium breve, when combined with a calorie-controlled diet, may aid in the weight loss of obese children and adolescents.
The global obesity treatment pharmaceuticals market is likely to be hampered by a lack of efficient healthcare infrastructure, as well as improper formulation and implementation of clinical practise guidelines and a scarcity of trained labourers in emerging regions.
Furthermore, the high cost of developing obesity medications and surgeries is projected to impede market growth. Furthermore, the extended gestation period required for research and development operations, as well as the inclusion of clinical studies required to evaluate the pharmaceuticals, add up to a large financial outlay.
Covid-19's introduction is projected to provide lucrative growth prospects for companies in the global obesity management medications market. Obesity, for example, can raise the death rate in COVID-19 by about 50%, according to researchers from the University of North Carolina in September 2020.
Over the projected period, obesity R&D is also expected to contribute in the growth of the worldwide obesity management medications market. For example, a study published in September 2020 by Novo Nordisk A/S suggested that GLP-1 medicines, which assist patients control their blood sugar levels, could be used to treat Covid-19 in diabetic and obese individuals.
Obesity prevalence is increasing in a number of developed countries. According to a report by the National Audit Office, the United Kingdom government is anticipated to fail in its objective to halve childhood obesity in England by 2030 by September 2020.
The worldwide obesity management pharmaceuticals market is predicted to develop due to the high prevalence of obesity in emerging economies. For example, WellNewMe, a Nigerian health technology business, claimed in September 2020 that obesity had become a growing health concern for many people in Sub-Saharan Africa, pointing out that roughly a third of Nigerian women were overweight or obese in 2018.
Comments
Post a Comment